References
Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522–2529.
Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364:2507–2516.
Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011;98:394–399.
Warenius HM, Jones M, Gorman T, et al. Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer 2000;83:1084–1095.
Carter S, Auer KL, Reardon DB, et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998;16:2787–2796.
Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and Radiosensitization. JAMA Dermatol 2013;10:1001.
Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. J Clin Oncol 2013;31:e220–e222.
Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. [Radiosensitization induced by vemurafenib]. Cancer Radiother 2013;17:304–307.
Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013;10:31.
Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013;23:175–178.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Baroudjian, B., Boussemart, L., Routier, E. et al. Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. Eur J Dermatol 24, 265–267 (2014). https://doi.org/10.1684/ejd.2014.2300
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2014.2300